Dubey Poornima, Sertorio Mathieu, Takiar Vinita
Department of Radiation Oncology, University of Cincinnati Barrett Cancer Center, 234 Goodman Street, ML 0757, Cincinnati, OH 45267, USA.
Cincinnati Department of Veterans Affairs (VA) Medical Center, 3200 Vine St., Cincinnati, OH 45220, USA.
Cancers (Basel). 2022 Jan 20;14(3):514. doi: 10.3390/cancers14030514.
Although radiation therapy (RT) is one of the mainstays of head and neck cancer (HNC) treatment, innovative approaches are needed to further improve treatment outcomes. A significant challenge has been to design delivery strategies that focus high doses of radiation on the tumor tissue while minimizing damage to surrounding structures. In the last decade, there has been increasing interest in harnessing high atomic number materials (Z-elements) as nanoparticle radiosensitizers that can also be specifically directed to the tumor bed. Metallic nanoparticles typically display chemical inertness in cellular and subcellular systems but serve as significant radioenhancers for synergistic tumor cell killing in the presence of ionizing radiation. In this review, we discuss the current research and therapeutic efficacy of metal nanoparticle (MNP)-based radiosensitizers, specifically in the treatment of HNC with an emphasis on gold- (AuNPs), gadolinium- (AGdIX), and silver- (Ag) based nanoparticles together with the metallic oxide-based hafnium (Hf), zinc (ZnO) and iron (SPION) nanoparticles. Both in vitro and in vivo systems for different ionizing radiations including photons and protons were reviewed. Finally, the current status of preclinical and clinical studies using MNP-enhanced radiation therapy is discussed.
尽管放射治疗(RT)是头颈癌(HNC)治疗的主要手段之一,但仍需要创新方法来进一步改善治疗效果。一个重大挑战是设计放射治疗策略,在将高剂量辐射聚焦于肿瘤组织的同时,尽量减少对周围结构的损伤。在过去十年中,人们越来越关注利用高原子序数材料(Z元素)作为纳米颗粒放射增敏剂,这些增敏剂还可以特异性地靶向肿瘤床。金属纳米颗粒在细胞和亚细胞系统中通常表现出化学惰性,但在存在电离辐射的情况下,可作为显著的放射增强剂,协同杀死肿瘤细胞。在本综述中,我们讨论了基于金属纳米颗粒(MNP)的放射增敏剂的当前研究和治疗效果,特别是在HNC治疗方面,重点讨论了基于金(AuNPs)、钆(AGdIX)和银(Ag)的纳米颗粒,以及基于金属氧化物的铪(Hf)、锌(ZnO)和铁(SPION)纳米颗粒。综述了针对包括光子和质子在内的不同电离辐射的体外和体内系统。最后,讨论了使用MNP增强放射治疗的临床前和临床研究的现状。
Nanomedicine (Lond). 2020-12
ACS Nano. 2024-1-16
Adv Drug Deliv Rev. 2015-12-19
Anticancer Res. 2014-1
Front Pharmacol. 2023-2-16
Technol Cancer Res Treat. 2023
Crit Rev Oncog. 2022
Nanomaterials (Basel). 2023-1-12
Cancer Drug Resist. 2021-3-19
Biotechnol Rep (Amst). 2020-10-28